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MicroRNA expression 
analysis identifies a subset of 
downregulated miRNAs in ALS 
motor neuron progenitors
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Valentina Bollati3, Nereo Bresolin1, Giacomo Pietro Comi1, Silvia Barabino  2, 
Monica Nizzardo  1 & Stefania Corti1
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder that is characterized by a progressive 
degeneration of motor neurons (MNs). The pathomechanism underlying the disease is largely unknown, 
even though increasing evidence suggests that RNA metabolism, including microRNAs (miRNAs) may 
play an important role. In this study, human ALS induced pluripotent stem cells were differentiated 
into MN progenitors and their miRNA expression profiles were compared to those of healthy control 
cells. We identified 15 downregulated miRNAs in patients’ cells. Gene ontology and molecular pathway 
enrichment analysis indicated that the predicted target genes of the differentially expressed miRNAs 
were involved in neurodegeneration-related pathways. Among the 15 examined miRNAs, miR-34a 
and miR504 appeared particularly relevant due to their involvement in the p53 pathway, synaptic 
vesicle regulation and general involvement in neurodegenerative diseases. Taken together our results 
demonstrate that the neurodegenerative phenotype in ALS can be associated with a dysregulation of 
miRNAs involved in the control of disease-relevant genetic pathways, suggesting that targeting entire 
gene networks can be a potential strategy to treat complex diseases such as ALS.
Amyotrophic lateral sclerosis (ALS) is the most common and severe form of motor neuron disease (MND) in 
adults1. It is a fatal neurodegenerative disorder that affects motor neurons (MNs) leading to progressive mus-
cle weakness and atrophy. Death usually occurs within 3–5 years after diagnosis due to respiratory failure1,2. 
Currently, due to the complexity of its etiopathogenesis and poor knowledge, there is no effective treatment and 
patients can rely only on supportive care and on Riluzole and Edaravone, the only two drugs approved for ALS 
treatment, which modestly prolong patient survival3.
The pathomechanisms underlying the disease are multifactorial and due to a complex interplay between 
genetics and environmental components, such as toxic exposure, diet and circulating inflammatory cytokines4. 
Patients without a familial history are generally recognized as sporadic (sALS) and account for the majority of 
cases, while familial forms of the disease (fALS) represent only 10% of clinical records5. To date, the most relevant 
genes associated with the disease are C9ORF72, SOD1, TARDBP and FUS, though several mutations in other 
genes have been reported to be involved in ALS pathogenesis6,7.
Currently, RNA pathway dysregulation appears to be a major contributor to ALS etiopathogenesis. Indeed, 
mutations in C9ORF72, which is the most common gene associated with ALS, lead to a toxic mRNA gain of func-
tion through RNA foci formation, and the subsequent sequestration and altered activity of RNA-binding proteins 
(RBPs)8. TDP-43 and FUS are also deeply involved in RNA metabolism. In a pathological context, such as cellular 
stress, the association between TDP-43, FUS and the mRNA can lead to aberrant phosphorylation, ubiquitination 
and the aggregation of proteins, as well as formation of stress granules (SGs)9. Aggregated RBPs are sequestered 
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in SGs, leading to the formation of cytoplasmic inclusions and to the disruption of RNA processing10. Moreover, 
both TDP-43 and FUS have been implicated in microRNA (miRNA) processing11.
miRNAs are short evolutionarily conserved noncoding single-stranded RNA molecules that regulate gene 
expression via RNA-dependent post-transcriptional silencing mechanisms12. They target the mRNA 3′-UTR, 
causing the mRNA downregulation either through its destabilization or protein translation inhibition13. Indeed, 
the degree of miRNA-mRNA target complementarity determines the fate of the target mRNA: a perfect anneal-
ing leads to transcript degradation, while an incomplete base-pairing is associated with translational repression, 
mRNA degradation or sequestration into cytoplasmic structures named P-bodies2.
Since a single miRNA can target multiple genes and a group of miRNAs may regulate the same target gene, 
these short sequences appear to be involved in almost all biological processes14–16. Indeed, miRNAs are crucial 
in determining cell homeostasis and biological fate, and they are usually subject to modification during dis-
ease pathogenesis17. Particularly, the control of gene expression by miRNAs is important for the maintenance of 
neuron survival and physiological functions, so that dysfunctions in miRNA biogenesis can have severe conse-
quences in neurological disease18–20.
miRNA biogenesis is a stepwise process strictly regulated by specific enzymatic complexes7. A surprising 
number of proteins associated with ALS are involved in miRNA processing21,22. For example, TDP-43 and FUS 
promote miRNA biogenesis by interacting with Drosha and Dicer, two key enzymes for processing miRNAs from 
precursors into mature molecules23,24. Moreover, mutations in TDP-43, FUS, and SOD1 activate a stress response 
pathway that leads to general decreased miRNA levels, which most likely contributes to MN degeneration25. 
Indeed, several studies describe miRNA dysregulation in ALS pathology7.
Due to the important roles of miRNAs in the fine-tuning of crucial cellular functions, they could represent an 
important tool for promoting modulations in biological pathways, which could explain, at least partially, complex 
diseases such as ALS. In fact, addressing the biological consequences of aberrant miRNA levels could contribute 
to the elucidation of the molecular mechanisms that lead to MN degeneration, thereby expanding our under-
standing of ALS pathogenesis.
In this study, we used induced pluripotent stem cells (iPSCs) to investigate miRNA-mediated pathogenic 
mechanisms in ALS. Patient-specific stem cells represent a promising in vitro disease model for ALS research, 
since they can be differentiated to different cell types harbouring the same patients’ genomic backgrounds. We 
studied miRNA dysregulation in MN progenitors differentiated from fALS and sALS patient iPSCs and we iden-
tified a subset of 15 differentially expressed miRNAs in patient-derived cells compared to healthy ones.
Gene Ontology enrichment and Reactome pathway analyses highlighted that the most involved deregulated 
pathways are associated with disease-relevant mechanisms, including synaptic vesicle synthesis, release, reuptake 
and degradation, apoptosis and epigenetic regulation of gene expression. Among the identified miRNAs, miR-34a 
and miR504 were further analyzed due to their implication in cell cycle regulation via the p53 pathway and their 
already described downregulation in neurological disorders26–30. Overall, our results confirmed the crucial role 
for miRNA deregulation in neurodegeneration and ALS. The identification of common downstream genetic path-
ways controlled by candidate miRNAs can lead to the discovery of pathological mechanisms and the development 
of therapeutic strategies that target multiple gene networks, increasing the chances of modifying a multifactorial 
disease such as ALS.
Results
Generation of iPSCs lines and MN progenitors as an in vitro model of ALS. We reprogrammed 
fibroblasts from two sporadic ALS patients (sALS n = 2), two familial ALS cases with SOD1 mutations (fALS 
n = 2) and two healthy subjects as controls (CTRL n = 2) into iPSCs (Supplementary Table S1) using a non-in-
tegrating reprogramming protocol based on Sendai virus technology31,32. The obtained iPSCs expressed typical 
stem cell markers including OCT4, SOX2, SSEA4 (Supplementary Fig. S1).
We differentiated ALS and CTRL-iPSCs using a specific dual SMAD inhibition protocol based on neural 
induction and exposure to a combination of small molecules that leads to the formation >90% MN progenitors 
in a 14-day time frame33. These cells were positive for lineage-specific markers including Olig2 and βIII Tubulin 
(TuJ1) (Fig. 1a). Quantitative PCR showed that expression levels of Olig2 and TuJ1 were comparable among 
control, sALS, and fALS cell lines, suggesting there is no difference in the proportion of MN progenitors among 
these lines (Fig. 1b).
miRNA expression profiles of MN progenitors show a miRNAs downregulation in ALS cells 
compared to controls. We next profiled the miRNA transcriptome of MN progenitors using the TaqMan® 
Low Density Array, which enabled the accurate quantitation of 754 human miRNAs.
The analysis was performed on ALS-MNs progenitors (n = 4, enclosing sALS and fALS samples in a unique 
biological group) versus CTRL-MNs (n = 2). We observed a decreased expression of 15 miRNAs in ALS-MN 
progenitors (Fig. 2a,b). We confirmed the results obtained with the Human Array MicroRNA cards using specific 
qPCR assays performed on a random subset of identified miRNAs (Fig. 2c, Supplementary Fig. S2). In particu-
lar, we tested miR-504 (P < 0.05), miR-429 (P < 0.05), miR-34a (P < 0.0001), miR-133a (P < 0.0001), miR-7-2* 
(P < 0.0001) and miR-1225-3p (P < 0.0001) (Fig. 2c).
Bioinformatics analysis on dysregulated miRNAs identifies deregulated pathways in ALS-MN 
progenitors. To identify target genes associated with the identified miRNAs we interrogated miRTarBase, 
one of the most comprehensively annotated and experimentally validated miRNA-target interactions databases, 
and Mirgate, which contains novel computationally predicted miRNA–mRNA interactions. We identified 2923 
validated target genes in MiRTarBase and 1018 putative targets in Mirgate.
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Then, to obtain a more reliable target dataset, we intersected the lists generated by both databases. Of the common 
368 genes, 278 genes were targeted by the same miRNAs thus representing the most stringent and reliable dataset.
In order to comprehensively describe the properties of these 278 target genes, we first performed Gene 
Ontology Enrichment analysis (GO). The analysis of biological processes revealed that the selected miRNAs were 
mainly involved in stem cell-related processes, such as regulation of epithelial to mesenchymal transition, mesen-
chyme development, regulation of stem cells differentiation and stem cell population (Fig. 3a).
Next, we analyzed our group of candidate genes with Reactome pathway over-representation to investigate the 
associated molecular pathways. Interestingly, the analysis showed that the putative targets of the selected miRNAs 
were associated with several pathways including chromatin modifying enzymes; oxidative stress; induced senes-
cence; GABA synthesis, release, reuptake and degradation (Fig. 3b).
Overall, these results suggest a potential role for miRNA reduction and particularly among those involved in 
neuronal processes and cell response injuries in ALS.
Gene expression analysis showed a deregulation of selected target genes. To experimentally 
characterize the involvement of the molecular pathways that had emerged from the Reactome analysis (Fig. 3b), 
we selected specific genes based on their expression in the central nervous system and their likely involvement 
in disease pathogenesis. We thus assayed, for quantitative Real Time PCR analysis (qRT-PCR) in ALS and 
CTRL-MN progenitors, Tumor protein p53 (TP53), MDM2 proto-oncogene (MDM2), and X-linked inhibitor of 
apoptosis (XIAP), associated with oxidative stress-induced senescence and apoptosis; Syntaxin 1A (STX1A) and 
Synaptotagmin 1 (SYT1), which are involved in synaptic vesicle trafficking; Sirtuin 1 (SIRT1), a specific is target 
of miR-34a28 (Supplementary Table S2). As shown in Fig. 4, qRT-PCR analysis revealed increased expression of 
TP53 (P < 0.001) and MDM2, while the transcript levels of XIAP did not change in the pathological samples. We 
further detected a significant reduction in STX1A transcript levels (P < 0.01), while we observed an increase in 
Figure 1. Immunocytochemistry (ICC) and qPCR performed on MN progenitors. (a) MN progenitors 
differentiated from fALS, sALS and control iPSCs (CTRL) expressed typical neuronal markers (Olig2, green; 
TuJ1, green). Nuclei are counterstained with DAPI (blue signal). Scale bars: Olig270 µm and TuJ1 50 µm.  
(b) Quantification of Olig2 and TuJ1 by qPCR performed on fALS, sALS and control (CTRL) MN progenitors 
(student t-test, values represent means + SEM).
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SYT1 albeit not statistically significant. Notably, all these genes are regulated by miR-34a and/or miR-504 suggest-
ing that these miRNAs may have a key role in ALS pathology. Finally, consistent with the downregulation of miR-
34a that we observed in our ALS-MN progenitors, we identified a significant upregulation of SIRT1 (P < 0.001).
Overall, these results further support the potential role of these genes as downstream targets of miR-34a and 
miR-504 in ALS pathogenesis.
Enoxacin treatment rescues miR-34a levels in ALS-iPSCs. According to previous reports7,25 we 
observed a preferential downregulation of miRNAs in ALS patients-derived cell lines. Because this reduction 
of miRNA levels may contribute to MN degeneration18,25, we examined the effect of enoxacin, a drug that was 
previously shown to increase miRNA levels25,34. Enoxacin is a fluoroquinolone antibiotic able to enhance the 
binding affinity of TRBP to pre-miRNAs, thereby increasing the activity of the pre-miRNA processing factor 
Dicer25,35,36. Importantly, enoxacin received an orphan designation for ALS treatment by the European Medicine 
Agency (EU/3/15/1459) because of its ability to improve miRNA biogenesis36. Among the identified miRNAs, 
we specifically focused on miR-34a and miR-504 due to their involvement in neurodegenerative pathways. As an 
internal control, we used miR-302 and miR-367, which are described in the literature as expressed in iPSCs under 
basal conditions. We analyzed the expression of the miRNAs in ALS-iPSCs versus control iPSCs either in the 
absence or in the presence of enoxacin. Consistent with the described effect of enoxacin, we detected an increased 
expression of all tested miRNAs, which was statistically significant for miR-34a and miR-504 (P < 0.01, Fig. 5a). 
Finally, we investigated whether enoxacin treatment could affect the levels of some of the proteins involved in 
miRNA biogenesis, such as Drosha, Dicer and Ago2. In general, we found that this drug did not appear to exert 
any effects on their protein levels (data not shown), confirming, as has already been reported in literature25, that 
enoxacin acts on Dicer activity and not on its protein level. We also demonstrated in our ALS-MN progenitors a 
downregulation of activating transcription factor 3 (ATF3, P < 0.01), already demonstrated as implicated in ALS 
pathology37. This decrease resulted mitigated after enoxacin treatment (Fig. 5b). The same trend was observed by 
western blot analysis (data not shown).
Discussion
The pathomechanisms underlying ALS are almost unknown, even though the role of alterations in RNA metab-
olism, including miRNA processing, has been increasingly recognized. miRNAs are tissue-specific small RNA 
molecules that can individually regulate several hundred targets. Since miRNAs are linked to gene regulatory 
networks implicated in neural induction, neuronal differentiation, and fate specification38, they can likely be 
Figure 2. MiRNA expression profile in ALS patients versus healthy controls. (a) Volcano plot data from 
TaqMan® Assays on microfluidics cards; data presented include sALS and fALS subjects in a unique 
biological group (ALS). (b) List of downregulated miRNAs in ALS-MN progenitors from the volcano plot 
analysis. (c) Validation of data derived from the microfluidics cards with specific qPCR assays confirmed 
the downregulation of miR-34a, miR-504, miR-429, miR-133a, miR-1225-3p, and miR-7-2* in ALS-MN 
progenitors (ALS) (***P < 0.0001 and *P < 0.05, student t-test, values represent means + SEM) compared to 
the controls (CTRL).
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implicated in MN development and in the etiology or progression of neurodegenerative diseases. Therefore, due 
to their role in controlling fundamental physiological functions in neurons2,39, the identification of deregulated 
miRNAs in pathological conditions could represent a strategy to understand disease mechanisms as well as to 
select novel therapeutic targets.
Growing evidence, such as recent data obtained for spinocerebellar ataxia type 1, suggests that adult-onset 
neurodegenerative diseases, including ALS, may also be rooted in development40. iPSC-based models allow the 
aetiopathology of ALS to be studied, including in the developmental stages that are otherwise inaccessible. For 
this reason, in this study, we derived MN progenitors33 directly from patient fibroblasts exploiting the iPSCs tech-
nology. Moreover, MN progenitors allowed us to characterize some molecular events related to ALS during the 
early stages of differentiation that can be important for the subsequent manifestation of ALS.
We performed miRNA profiling on MN progenitors through micro fluidic cards technology. Consistent with 
previous reports that observed a general downregulation of miRNAs in ALS7, we identified 15 significantly down-
regulated miRNAs in our ALS lines enclosing sALS and fALS samples as a unique biological group. Indeed, even 
if fALS and sALS can have different pathological mechanisms, we think that finding a common target dereg-
ulated in both sporadic and familiar patients can be useful either to understand the pathogenesis or to find a 
common therapeutic strategy. Bioinformatics analysis allowed the identification of 278 genes that are targeted by 
a common set of dysregulated miRNAs. Gene Ontology and Reactome pathway analysis showed that the main 
significantly enriched biological processes were specifically related to several pathways including programmed 
cell death, oxidative stress-induced senescence, synaptic vesicles synthesis, release, reuptake and degradation, 
apoptosis and epigenetic regulation of gene expression. Among the 15 miRNAs identified in our study, miR-34a 
Figure 3. GO and Molecular Pathway analysis performed on the 278 genes identified by bioinformatics.  
(a) GO enrichment analysis showed the most significant biological processes enriched in ALS-MN progenitors 
(P < 0.05) and the list of genes associated with the 4 most enriched processes. (b) Table of selected pathways 
with the related genes emerging from the Reactome analysis (P < 0.05).
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and miR-504 were relevant candidates to be further investigated for target validation. We focused on genes that 
are involved in the main pathways that are consistent with degeneration processes occurring in ALS, namely in 
apoptosis, epigenetic regulation, and in synaptic vescicles metabolism.
Based on the Reactome analysis, miR-34a was associated with almost all the affected pathways and related 
genes. Literature evidence shows that this miRNA is involved in cell cycle regulation, induction of apoptosis 
after cell damage, and autophagy29,41,42. Intriguingly, miR-34a and miR-504 share many molecular pathways 
related to apoptosis43,44. miR-34a has already been found to be downregulated in the spinal cord and brain stem 
of SOD1G93A transgenic mice, at different stages of the disease and has been considered an apoptotic-related 
miRNA30, while miR-504 deregulation has not yet been described in the context of ALS. miR-34a is a direct tran-
scriptional target of TP5345 gene while miR-504 is a direct upstream negative regulator of TP53 protein expres-
sion43,44. Moreover, the activation of TP53 can result in transcription of miR-34, which in turn promotes TP53 
expression44. Finally, the promoter region of the miR-34 gene is regulated by epigenetic mechanisms and pro-
moter demethylation can induce miR-34a expression, TP53 transcription and the subsequent regulation of genes 
involved in cell cycle control44. Interestingly, TP53 and related proteins have already been associated with neu-
rodegenerative diseases and motor neuronal cell death both in patients and in ALS murine models46,47. For these 
reasons, we further investigated the mRNA level of TP53 and of MDM2 and XIAP, two other apoptosis-related 
genes that were identified as miR-34a and miR-504 targets in our bioinformatics analysis. We found increased 
TP53 and MDM2 transcript levels in ALS-MN progenitors. MDM2 binds p53 and controls its transcriptional 
activity and stability through an autoregolatory feedback mechanism48. However, the simultaneous upregulation 
of TP53 and MDM2 has been already described in mouse skeletal muscles in ALS mice49. With regards to XIAP, 
we did not observe any significant differences in terms of gene expression in ALS cells compared to controls. It 
has been reported that XIAP is decreased in the disease and its overexpression in spinal cord neurons in ALS mice 
displayed beneficial effects on survival50.
Epigenetic processes can alter the genetic information as a result of environmental signals, and these mecha-
nisms are particularly important in the neurodegenerative field, which makes the epigenome an attractive ther-
apeutic target51. In ALS, it has been reported that several environmental insults can trigger the release of free 
radicals leading to oxidative stress, epigenetic modifications and finally changes in gene expression52. In this con-
text, it is worth mentioning that the promoter region of the miR-34 gene is regulated by epigenetic mechanisms 
and promoter demethylation can induce miR-34a expression, TP53 activation and the regulation of various genes 
involved in the cell cycle44.
In yeast sirtuin proteins are known to regulate epigenetic gene silencing. The human SIRT1 gene is a direct 
target of miR-34a53. We assayed the level of SIRT1, and observed a statistically significant upregulation consist-
ent with the downregulation of miR-34a in ALS-MN progenitors. Interestingly, SIRT1 was shown to protect 
cells from oxidative stress54 and apoptosis55. Thus, increased expression of SIRT1 may represent a pro-survival 
response for ALS MN progenitors.
Based on the known role of synaptic vesicles at neuromuscular junctions, we investigated the expression of 
STX1A and SYT1, two genes identified in the Reactome analysis, targeted by miR-34, and involved in synaptic 
Figure 4. Gene expression analysis of selected target genes identified. Specific qPCR gene expression analysis 
for SIRT1, STX1A, SYT1, XIAP, MDM2 and TP53 (***P < 0.001 and **P < 0.01, student t-test, values represent 
means + SEM) in ALS cells (ALS) compared to the control cells (CTRL).
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functions. In fact, synapses are basic structural and functional units of the central nervous system-muscles con-
nection that are highly vulnerable to pathological conditions, particularly in neurodegenerative diseases. In ALS, 
mutations of SOD1, TDP43 and FUS have already been linked to synaptic dysfunctions56. Particularly, presyn-
aptic alterations appear to be early symptoms of neuronal disorders. Interestingly, our gene expression analysis 
Figure 5. miRNA expression analysis in control and ALS iPSCs and ATF3 quantification after enoxacin 
treatment. (a) qPCR experiments performed on miR-34a, miR-504, miR-367 and miR-302b in control (CTRL) 
and ALS iPSCs (ALS) treated or not treated with 100 μM enoxacin for 48 hours. Enoxacin treatment increased 
the amount of miRNAs in both control and ALS iPSCs (***P < 0.0001 and **P < 0.01, student t-test, values 
represent means + SEM). The experiment was repeated three times. (b) qPCR experiments performed on ATF3 
in control (CTRL) and ALS-MN progenitors (ALS) treated or not treated with 100 μM enoxacin for 48 hours. 
ALS displayed significant low levels of ATF3 (**P < 0.01, student t-test, values represent means + SEM).
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confirmed the dysregulated expression of STX1A, a member of the syntaxin superfamily that is involved in 
neurotransmitter release at the presynaptic membrane. We found a significant decrease of STX1A levels in our 
ALS cells, which confirmed data already published about syntaxin family members in the spinal cord from ALS 
patients57. We also assayed SYT1 levels since this protein acts as a key regulator for synaptic vesicle exocytosis 
and endocytosis, regulating their docking in response to the presence of calcium58 and because it has already 
been associated with synaptic transmission defects in another murine model of a MN disease, Spinal Muscular 
Atrophy (SMA)59. Moreover, SYT1 downregulation has been reported in nerve terminals from highly affected 
muscles, which seems to be associated with SMA mouse muscle vulnerability60. However, in the spinal cords 
of SOD1 mice, higher SYT1 expression was observed and was linked to the altered calcium concentrations and 
ALS-linked excitotoxicity61. Of note, we confirmed an upregulation of SYT1 transcript levels in our ALS-MN pro-
genitors. Thus, our gene expression results for STX1A and SYT1 support a key role for these proteins in synaptic 
vesicle trafficking changes in ALS that requires further investigations.
Finally, we investigated the potential therapeutic effect of enoxacin on miRNA levels in ALS. Enoxacin is an 
antibiotic that recently received an orphan designation for ALS treatment by the EMA (EU/3/15/1459) thanks 
to its ability to increase Dicer activity. Indeed, this compound enhances the binding affinity of TAR RNA bind-
ing protein to pre-miRNAs, thereby increasing pre-miRNA processing by Dicer35,36. Since Dicer is known to be 
crucial in miRNA biogenesis, enoxacin is expected to revert the general miRNA downregulation related to ALS 
disease. Therefore, we treated ALS and control iPSCs with enoxacin observing a slight increase in miRNAs levels 
in the treated cells compared to untreated cells. We have already shown that fully differentiated MNs in ALS had 
decreased survival that correlated with variations in the activation of the apoptotic pathway after long term cul-
ture62. Even if in the present study, we did not observe a difference among control, sALS, and fALS MN progen-
itors obtainment, we found decreased expression of activating transcription factor 3 (ATF3). Expression of ATF3 
prevents cell death and promotes neurite formation and elongation that induces the expression of survival and 
growth-associated genes. Moreover, it has already been demonstrated that overexpression of ATF3 in the MN of 
SOD1G93A mice supports their survival and axonal integrity maintenance37. Here, we demonstrated that enoxa-
cin treatment may slightly enhance ATF3 levels in ALS, suggesting that the general upregulation of miRNA levels 
can be beneficial by regulating key genes that modulate pathological phenotypes. Overall, our results highlight 
the crucial role of miRNAs in ALS physiopathology, providing insights into pathogenic mechanisms. In particu-
lar, we identified two miRNAs, miR-34a and miR504, as well as their downstream pathways, in particular apop-
tosis and synaptic vesicle regulation, that can account for ALS pathological mechanisms and represent potential 
therapeutic targets. The identification of common pathways associated with different deregulated miRNAs in 
ALS could be crucial for identifying therapeutic target. ALS is a complex disease that involves several biological 
pathways, and a suitable innovative and effective therapy likely has to rely on a multi-faceted approach.
These analyses should be further examined in additional cell lines obtained from patients carrying different 
mutations to detect shared pathogenic mechanisms. Moreover, miRNA-based therapies should be tested to con-
firm the relevance of the identified pathways.
Material and Methods
iPSCs generation. The studies involving human samples were conducted in accordance with the Code 
of Ethics of the World Medical Association (Declaration of Helsinki) and with national legislation and institu-
tional guidelines. After obtaining informed consent, we reprogrammed fibroblasts derived from skin biopsies 
(Eurobiobank, ethical committee approval at the IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico) 
from ALS (n = 2 sALS and n = 2 fALS subjects harbouring mutations in SOD1) and healthy subjects (n = 2) into 
iPSCs using the CytoTune®-iPS 2.0 Sendai Reprogramming Kit (Life Technologies, Carlsbad, CA, USA) accord-
ing to manufacturer’s instructions. The kit contains 3 vectors derived from a modified and non-integrating form 
of Sendai virus (SeV) which carries the 4 Yamanaka’s factors Oct4, Sox2, Klf4 and c-Myc63.
Fibroblasts derived from subject’ biopsies were cultured in DMEM high glucose (Life Technologies, Carlsbad, 
CA, USA), with 15% fetal bovine serum (FBS) (Euroclone, Milan, Italy) and infected with Sendai viruses. After 
two weeks the first iPSC colonies were obtained, mechanically picked and maintained in Essential 8 Medium 
(Life Technologies, Carlsbad, CA, USA) on plates covered with a thin cultrex layer (Cultrex® Stem Cell Qualified 
Reduced Growth Factor Basement Membrane Extract PathClear®; Thema Ricerca, Castenaso, Italy). Information 
about the patients from whom the iPSC lines were derived is provided in Supplementary Table S1.
We performed Enoxacin treatment in iPSC lines by adding 100 µM Enoxacin to cell media (RNAi Enhancer 
Enoxacin Sodium Salt; Millipore, Burlington, MA, USA). We collected samples 48 hours after treatment and we 
stored cell pellets at −80 °C.
iPSC differentiation into MN progenitors. iPSCs were differentiated into MN progenitors using a 14 
days multistep protocol. We slightly modified a previously published protocol33. Specifically, iPSCs were plated 
in neural induction medium (DMEM/F12, 1x Glutamax, 0.5x MEAA, and 1x penicillin/streptomycin) (Life 
Technologies, Carlsbad, CA, USA) supplemented with 10 µM SB (Sigma Aldrich, Saint Louis, MO, USA) and 
0,2 µM LDN (Stemgent, Cambridge, MA, USA) for 7 days. We subsequently promoted MN progenitors’ forma-
tion by using a combination of small molecules that address specific caudal differentiation: 1 µM Retinoic Acid 
(RA; Sigma Aldrich, Saint Louis, MO, USA) and 200 ng/mL of Sonic Hedgehog (Shh; Sigma Aldrich, Saint Louis, 
MO, USA) were added for additional 7 days. Cells were collected and stored at −80 °C for the analysis.
Immunocytochemistry analysis. Cells were fixed with 4% paraformaldehyde for 10 minutes, permeabi-
lized with 0,25% TritonX-100 and subsequently blocked with 10% BSA and 0,3% Triton X-100 in 1x PBS solution, 
for 1 h at room temperature (RT). Slides were incubated overnight at 4 °C with specific primary antibodies and 
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incubated with the appropriate secondary antibodies conjugated with Alexa-Fluor 488 or 568 (anti-mouse, rabbit 
or goat, 1:1000 Life Technologies, Carlsbad, CA, USA) for 1 hour and 30 minutes at RT. Image acquisition was 
performed with a LEICA LCS2 microscope.
The following antibodies and dilutions were used for iPSC staining: SSEA-4 (mouse 1:500, Chemicon 
International, Temecula, CA, USA), OCT4 (mouse 1:500, Chemicon, International, Temecula, CA, USA), and 
SOX2 (mouse 1:500, Chemicon, International, Temecula, CA, USA). For MN progenitor staining, we employed 
TuJ1 (anti-rabbit 1:400, Millipore, Burlington, MA, USA) and Olig2 (anti-mouse 1:100, Sigma Aldrich, Saint 
Louis, MO, USA) antibodies.
Total RNA and miRNA isolation. For each sample, both total RNA and miRNA were extracted using mir-
Vana™ miRNA Isolation Kit (Life Technologies, Carlsbad, CA, USA). Total RNA was eluted in 70 µL of pre-heated 
(95 °C) Elution Solution. To separate large RNA species from the enriched small RNAs, we sequentially immobi-
lized the large RNAs on two filter cartridges and finally collected the flow-through containing mostly the small 
RNA fraction. The purified small RNA fraction was eluted in 30 µL of pre-heated Elution Solution. To identify the 
RNA profile and obtain information about RNA integrity the miRNA samples were analyzed by 2100 Bioanalyzer 
(Agilent Tecnologies, Santa Clara, CA), using Agilent RNA 6000 Nano Kit. After miRNA isolation samples were 
stored at −80 °C until further steps.
Profiling by TaqMan® Array Micro Fluidic Cards. We used the TaqMan® MicroRNA Reverse 
Transcription Kit and related Megaplex™ RT Primers to synthesize single-stranded cDNA from the small RNA 
samples. For a full miRNA profile, we performed two separate reverse transcription reactions for each sample 
using pool A or pool B MegaplexTM RT primers and 250 ng of RNA as template. The DNA polymerase from the 
TaqMan® Universal PCR Master Mix amplifies the target cDNA using sequence-specific primers and probes on 
the TaqMan® Low Density Array (TLDA-, Life Technologies, Carlsbad, CA, USA) by 7900HT Fast Real Time 
PCR System (Applied Biosystem, Foster City, CA, USA). We assayed two, TLDA, pre-loaded 384-well microflu-
idic cards with 754 spotted assays specific to human miRNAs, for each sample with respect to the MegaplexTM RT 
product A and B. Each card contains four control assays; 3 selected candidate endogenous control assays (RNU6, 
RNU44 and RNU48, the first being in quadruplicate) and 1 negative control assay. We performed relative quan-
tification (ΔΔCt) using the Gene Expression Suite Software (Life Technologies, Carlsbad, CA, USA) to process 
the miRNA expression data, using RNU6 as control endogenous assay, automatic baseline settings and a thresh-
old of 0.2. miRNAs with Ct ˃35 were considered as undetermined. Gene Expression Suite Software included the 
student’s t-test for sample group comparisons and built Volcano Plot comparing the size of the fold change (bio-
logical significance) to the statistical significance (p-value). miRNAs identified as dysregulated were examined 
with two different miRNA databases aiming to identify validated and predicted target genes and related pathways 
(http://miRTarBase.mbc.nctu.edu.tw/ and http://mirgate.bioinfo.cnio.es/miRGate/).
Gene Ontology enrichment and Reactome pathway analysis. Gene Ontology enrichment analysis 
was performed with the PANTHER (Protein ANalysis THrough Evolutionary Relationships) classification system 
(http://www.pantherdb.org), using the identified 278 miRNA target genes as queries for the statistical overrep-
resentation test and the most updated (at the time of analysis) Homo sapiens genes annotations as reference set; only 
the over-represented biological process terms with a p-value < 0.05 have been chosen to be reported in the graphs.
Reactome pathway analysis was performed with the “Analysis tool” available on https://reactome.org website 
and using the same genes as queries and Homo sapiens genes as reference set; selected overrepresented pathways, 
with p-value < 0.05, have been selected for further analysis.
Validation by Taqman® MicroRNA Assays. For the 15 candidate miRNAs we performed reverse tran-
scription using the TaqMan® MicroRNA Reverse Transcription Kit (Life Technologies, Foster City, CA) and 
specific 5x RT primers to synthesize single-stranded cDNA from 10 ng of total RNA samples. Each RT product 
was amplified using the TaqMan® Universal Master Mix II No AmpErase® UNG (Life Technologies, Carlsbad, 
CA, USA) and the appropriate 20x TaqMan® MicroRNA Assays (probe ID available upon request) to evaluate 
miRNA expression on the 7500 Real Time PCR System (Software 2.01, Applied Biosystems, Foster City, CA, 
USA). miRNA expression levels were normalized to the average levels of the endogenous small RNA control U6 
snRNA and referred to the relevant control samples.
mRNA expression by q- PCR. First-strand cDNA was synthesized from 1 μg of total RNA with random 
hexamer primers using the First-Strand cDNA Synthesis kit (GE Healthcare, Little Chalfont, UK).
The expression of markers of MN progenitors OLIG2 (Hs00300164_s1) and TUBB3 (Hs00801390_s1) was 
evaluated by quantitative real-time PCR analysis by means of the ΔΔCt method on a 7500 Real Time PCR 
System (Software 2.01, Applied Biosystems, Foster City, CA, USA).
We assayed the gene expression of STX1A (Hs00270282_m1), SIRT1 (Hs01009006_m1), TP53 (Hs01034249_
m1), SYT1 (Hs00194572_m1), XIAP (Hs00745222_s1), MDM2 (Hs00540450_s1) and ATF3 (Hs00231069_m1) 
by quantitative real-time PCR analysis by means of the ΔΔCt method. The expression levels of each gene were 
normalized to the average levels of the housekeeping gene 18S (Hs99999901_s1) and referred to the relevant 
control samples.
Statistical analysis. Statistical analyses were performed in the GraphPad Prism 5 software. All q-PCR 
counting data were expressed as mean the with SEM. The two-tailed, unpaired Student’s t test was utilized to 
compare two groups. The null hypothesis was rejected at a level of 0.05.
www.nature.com/scientificreports/
1 0SCIENTIFIC RepoRts |  (2018) 8:10105  | DOI:10.1038/s41598-018-28366-1
References
 1. Hardiman, O. et al. Amyotrophic lateral sclerosis. Nature reviews. Disease primers 3, 17071, https://doi.org/10.1038/nrdp.2017.71 
(2017).
 2. Paez-Colasante, X., Figueroa-Romero, C., Sakowski, S. A., Goutman, S. A. & Feldman, E. L. Amyotrophic lateral sclerosis: 
mechanisms and therapeutics in the epigenomic era. Nature reviews. Neurology 11, 266–279, https://doi.org/10.1038/
nrneurol.2015.57 (2015).
 3. Miller, R. G. & Appel, S. H. Introduction to supplement: the current status of treatment for ALS. Amyotrophic lateral sclerosis & 
frontotemporal degeneration 18, 1–4, https://doi.org/10.1080/21678421.2017.1361447 (2017).
 4. Al-Chalabi, A. & Hardiman, O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nature reviews. Neurology 
9, 617–628, https://doi.org/10.1038/nrneurol.2013.203 (2013).
 5. Taylor, J. P., Brown, R. H. Jr & Cleveland, D. W. Decoding ALS: from genes to mechanism. Nature 539, 197–206, https://doi.
org/10.1038/nature20413 (2016).
 6. Li, H. F. & Wu, Z. Y. Genotype-phenotype correlations of amyotrophic lateral sclerosis. Translational neurodegeneration 5, 3, https://
doi.org/10.1186/s40035-016-0050-8 (2016).
 7. Rinchetti, P., Rizzuti, M., Faravelli, I. & Corti, S. MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis. 
Molecular neurobiology, https://doi.org/10.1007/s12035-017-0537-z (2017).
 8. Morgan, S. & Orrell, R. W. Pathogenesis of amyotrophic lateral sclerosis. British medical bulletin 119, 87–98, https://doi.org/10.1093/
bmb/ldw026 (2016).
 9. Droppelmann, C. A., Campos-Melo, D., Ishtiaq, M., Volkening, K. & Strong, M. J. RNA metabolism in ALS: when normal processes 
become pathological. Amyotrophic lateral sclerosis & frontotemporal degeneration 15, 321–336, https://doi.org/10.3109/21678421.2
014.881377 (2014).
 10. Narayanan, R. K. et al. Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain. 
Amyotrophic lateral sclerosis & frontotemporal degeneration 14, 252–260, https://doi.org/10.3109/21678421.2012.734520 (2013).
 11. Da Cruz, S. & Cleveland, D. W. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Current opinion in neurobiology 
21, 904–919, https://doi.org/10.1016/j.conb.2011.05.029 (2011).
 12. Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nature reviews. 
Genetics 11, 597–610, https://doi.org/10.1038/nrg2843 (2010).
 13. Huntzinger, E. & Izaurralde, E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nature 
reviews. Genetics 12, 99–110, https://doi.org/10.1038/nrg2936 (2011).
 14. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
 15. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233, https://doi.org/10.1016/j.cell.2009.01.002 
(2009).
 16. Hashimoto, Y., Akiyama, Y. & Yuasa, Y. Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. 
PloS one 8, e62589, https://doi.org/10.1371/journal.pone.0062589 (2013).
 17. Engels, B. M. & Hutvagner, G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 25, 
6163–6169, https://doi.org/10.1038/sj.onc.1209909 (2006).
 18. Haramati, S. et al. miRNA malfunction causes spinal motor neuron disease. Proceedings of the National Academy of Sciences of the 
United States of America 107, 13111–13116, https://doi.org/10.1073/pnas.1006151107 (2010).
 19. Lu, J. et al. Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson’s 
disease. Neuroscience 365, 70–82, https://doi.org/10.1016/j.neuroscience.2017.09.033 (2017).
 20. Quinlan, S., Kenny, A., Medina, M., Engel, T. & Jimenez-Mateos, E. M. MicroRNAs inNeurodegenerative Diseases. International 
review of cell and molecular biology 334, 309–343, https://doi.org/10.1016/bs.ircmb.2017.04.002 (2017).
 21. Honda, D. et al. The ALS/FTLD-related RNA-binding proteins TDP-43 and FUS have common downstream RNA targets in cortical 
neurons. FEBS open bio 4, 1–10, https://doi.org/10.1016/j.fob.2013.11.001 (2013).
 22. Robberecht, W. & Philips, T. The changing scene of amyotrophic lateral sclerosis. Nature reviews. Neuroscience 14, 248–264, https://
doi.org/10.1038/nrn3430 (2013).
 23. Kawahara, Y. & Mieda-Sato, A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. 
Proceedings of the National Academy of Sciences of the United States of America 109, 3347–3352, https://doi.org/10.1073/
pnas.1112427109 (2012).
 24. Morlando, M. et al. FUS stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment. The EMBO journal 
31, 4502–4510, https://doi.org/10.1038/emboj.2012.319 (2012).
 25. Emde, A. et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for 
ALS. The EMBO journal 34, 2633–2651, https://doi.org/10.15252/embj.201490493 (2015).
 26. Ba, H. V., Reddy, B. V. & Hwang, I. Role of calpastatin in the regulation of mRNA expression of calpain, caspase, and heat shock 
protein systems in bovine muscle satellite cells. In vitro cellular & developmental biology. Animal 51, 447–454, https://doi.
org/10.1007/s11626-014-9849-8 (2015).
 27. Choi, S. Y. et al. Post-transcriptional regulation of SHANK3 expression by microRNAs related to multiple neuropsychiatric 
disorders. Molecular brain 8, 74, https://doi.org/10.1186/s13041-015-0165-3 (2015).
 28. Li, L. H. et al. Mutant presenilin2 promotes apoptosis through the p53/miR-34a axis in neuronal cells. Brain research 1662, 57–64, 
https://doi.org/10.1016/j.brainres.2017.01.034 (2017).
 29. Modi, P. K., Jaiswal, S. & Sharma, P. Regulation of Neuronal Cell Cycle and Apoptosis by MicroRNA 34a. Molecular and cellular 
biology 36, 84–94, https://doi.org/10.1128/MCB.00589-15 (2016).
 30. Zhou, F. et al. Screening the expression characteristics of several miRNAs in G93A-SOD1 transgenic mouse: altered expression of 
miRNA-124 is associated with astrocyte differentiation by targeting Sox2 and Sox9. Journal of neurochemistry, https://doi.
org/10.1111/jnc.14229 (2017).
 31. Corti, S. et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Science 
translational medicine 4, 165ra162, https://doi.org/10.1126/scitranslmed.3004108 (2012).
 32. Nizzardo, M. et al. Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves 
the phenotype of an amyotrophic lateral sclerosis model. Human molecular genetics 23, 342–354, https://doi.org/10.1093/hmg/
ddt425 (2014).
 33. Du, Z. W. et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nature 
communications 6, 6626, https://doi.org/10.1038/ncomms7626 (2015).
 34. Smalheiser, N. R., Zhang, H. & Dwivedi, Y. Enoxacin Elevates MicroRNA Levels in Rat Frontal Cortex and Prevents Learned 
Helplessness. Frontiers in psychiatry 5, 6, https://doi.org/10.3389/fpsyt.2014.00006 (2014).
 35. Melo, A. et al. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxidative medicine and 
cellular longevity 2011, 467180, https://doi.org/10.1155/2011/467180 (2011).
 36. Shan, G. et al. A small molecule enhances RNA interference and promotes microRNA processing. Nature biotechnology 26, 933–940, 
https://doi.org/10.1038/nbt.1481 (2008).
 37. Seijffers, R. et al. ATF3 expression improves motor function in the ALS mouse model by promoting motor neuron survival and 
retaining muscle innervation. Proceedings of the National Academy of Sciences of the United States of America 111, 1622–1627, 
https://doi.org/10.1073/pnas.1314826111 (2014).
www.nature.com/scientificreports/
1 1SCIENTIFIC RepoRts |  (2018) 8:10105  | DOI:10.1038/s41598-018-28366-1
 38. Stappert, L., Roese-Koerner, B. & Brustle, O. The role of microRNAs in human neural stem cells, neuronal differentiation and 
subtype specification. Cell and tissue research 359, 47–64, https://doi.org/10.1007/s00441-014-1981-y (2015).
 39. Bicker, S. & Schratt, G. MicroRNAs in ALS: small pieces to the puzzle. The EMBO journal 34, 2601–2603, https://doi.org/10.15252/
embj.201592805 (2015).
 40. Edamakanti, C. R., Do, J., Didonna, A., Martina, M. & Opal, P. Mutant ataxin1 disrupts cerebellar development in spinocerebellar 
ataxia type 1. The Journal of clinical investigation, https://doi.org/10.1172/JCI96765 (2018).
 41. Mollinari, C. et al. miR-34a regulates cell proliferation, morphology and function of newborn neurons resulting in improved 
behavioural outcomes. Cell death & disease 6, e1622, https://doi.org/10.1038/cddis.2014.589 (2015).
 42. Morgado, A. L. et al. MicroRNA-34a Modulates Neural Stem Cell Differentiation by Regulating Expression of Synaptic and 
Autophagic Proteins. Molecular neurobiology 51, 1168–1183, https://doi.org/10.1007/s12035-014-8794-6 (2015).
 43. Hu, W. et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Molecular cell 38, 689–699, https://doi.
org/10.1016/j.molcel.2010.05.027 (2010).
 44. McCubrey, J. A. et al. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget 8, 
14221–14250, https://doi.org/10.18632/oncotarget.13991 (2017).
 45. Raver-Shapira, N. et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular cell 26, 731–743, 
https://doi.org/10.1016/j.molcel.2007.05.017 (2007).
 46. Gonzalez de Aguilar, J. L. et al. Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: 
evidence for the implication of the p53 signaling pathway. Neurobiology of disease 7, 406–415, https://doi.org/10.1006/
nbdi.2000.0295 (2000).
 47. Ranganathan, S. & Bowser, R. p53 and Cell Cycle Proteins Participate in Spinal Motor Neuron Cell Death in ALS. The open pathology 
journal 4, 11–22, https://doi.org/10.2174/1874375701004010011 (2010).
 48. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (New York, N.Y.) 303, 
844–848, https://doi.org/10.1126/science.1092472 (2004).
 49. von Grabowiecki, Y. et al. Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-
atrophic ubiquitin ligase Trim63. eLife 5, https://doi.org/10.7554/eLife.10528 (2016).
 50. Wootz, H., Hansson, I., Korhonen, L. & Lindholm, D. XIAP decreases caspase-12 cleavage and calpain activity in spinal cord of ALS 
transgenic mice. Experimental cell research 312, 1890–1898, https://doi.org/10.1016/j.yexcr.2006.02.021 (2006).
 51. Mattick, J. S., Amaral, P. P., Dinger, M. E., Mercer, T. R. & Mehler, M. F. RNA regulation of epigenetic processes. BioEssays: news and 
reviews in molecular, cellular and developmental biology 31, 51–59, https://doi.org/10.1002/bies.080099 (2009).
 52. Belzil, V. V., Katzman, R. B. & Petrucelli, L. ALS and FTD: an epigenetic perspective. Acta neuropathologica 132, 487–502, https://
doi.org/10.1007/s00401-016-1587-4 (2016).
 53. Zhang, F. et al. Roles of microRNA-34a targeting SIRT1 in mesenchymal stem cells. Stem cell research & therapy 6, 195, https://doi.
org/10.1186/s13287-015-0187-x (2015).
 54. Singh, P., Hanson, P. S. & Morris, C. M. SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in 
Parkinson’s disease. BMC neuroscience 18, 46, https://doi.org/10.1186/s12868-017-0364-1 (2017).
 55. Zhao, G. et al. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in 
pancreatic cancer cells. Gene therapy 18, 920–928, https://doi.org/10.1038/gt.2011.81 (2011).
 56. Bae, J. R. & Kim, S. H. Synapses in neurodegenerative diseases. BMB reports 50, 237–246 (2017).
 57. Ikemoto, A., Nakamura, S., Akiguchi, I. & Hirano, A. Differential expression between synaptic vesicle proteins and presynaptic 
plasma membrane proteins in the anterior horn of amyotrophic lateral sclerosis. Acta neuropathologica 103, 179–187, https://doi.
org/10.1007/s004010100449 (2002).
 58. Li, Y. C., Chanaday, N. L., Xu, W. & Kavalali, E. T. Synaptotagmin-1-and Synaptotagmin-7-Dependent Fusion Mechanisms Target 
Synaptic Vesicles to Kinetically Distinct Endocytic Pathways. Neuron 93, 616-+, https://doi.org/10.1016/j.neuron.2016.12.010 
(2017).
 59. Dale, J. M. et al. The spinal muscular atrophy mouse model, SMA Delta 7, displays altered axonal transport without global 
neurofilament alterations. Acta neuropathologica 122, 331–341, https://doi.org/10.1007/s00401-011-0848-5 (2011).
 60. Tejero, R., Lopez-Manzaneda, M., Arumugam, S. & Tabares, L. Synaptotagmin-2, and -1, linked to neurotransmission impairment 
and vulnerability in Spinal Muscular Atrophy. Human molecular genetics 25, 4703–4716, https://doi.org/10.1093/hmg/ddw297 
(2016).
 61. Bonifacino, T. et al. Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a pre-
symptomatic stage of the disease. Neurobiology of disease 95, 122–133, https://doi.org/10.1016/j.nbd.2016.07.011 (2016).
 62. Nizzardo, M. et al. Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype. Scientific 
reports 6, 21301, https://doi.org/10.1038/srep21301 (2016).
 63. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872, https://
doi.org/10.1016/j.cell.2007.11.019 (2007).
Acknowledgements
The contribution of the smallRNALS research grant by the AriSLA Foundation to SC and SB as well as the 
Italian Ministry of Health (RF-2013-023555764) and Regione Lombardia TRANS-ALS to GPC is gratefully 
acknowledged. We wish to thank Associazione Amici del Centro Dino Ferrari for the support.
Author Contributions
M.R. and L.C. performed the in vitro experiments. G.F. performed the bioinformatics analysis. V.M. performed 
the q-PCR analysis. L.D. performed the TaqMan® Array Micro Fluidic Cards. M.R. participated in all the 
experiments. V.B., N.B., G.P.C. and S.B. contributed ideas and supported the work. S.C. and M.N. conceived the 
experiments and wrote the manuscript. M.R. and L.C. contributed to writing the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-28366-1.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 2SCIENTIFIC RepoRts |  (2018) 8:10105  | DOI:10.1038/s41598-018-28366-1
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
